Radiometer Medical ApS Sustainability Profile
Radiometer Medical ApS, a leading provider of innovative diagnostic solutions, is headquartered in Denmark (DK) and operates extensively across Europe, the Americas, and Asia. Founded in 1935, the company has established itself in the medical technology industry, specialising in blood gas analysis, immunoassay, and clinical chemistry. Radiometer's core products, including the ABL blood gas analyser and the immunoassay platform, are renowned for their precision and speed, enabling healthcare professionals to make informed decisions quickly. The company is recognised for its commitment to quality and innovation, having achieved numerous milestones in diagnostic technology. With a strong market position, Radiometer Medical ApS continues to enhance patient care through its advanced solutions, making significant contributions to the field of laboratory diagnostics.
DitchCarbon Score
How does Radiometer Medical ApS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Machinery and Equipment industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Radiometer Medical ApS's score of 57 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Radiometer Medical ApS, headquartered in Denmark (DK), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family under Danaher Corporation, which influences its climate commitments and initiatives. As a current subsidiary of Danaher Corporation, Radiometer Medical ApS inherits climate-related targets and performance metrics from its parent company. Danaher has established various sustainability initiatives, including commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These initiatives aim to drive significant reductions in greenhouse gas emissions across their operations. While specific reduction targets for Radiometer Medical ApS are not detailed, the overarching goals set by Danaher Corporation reflect a commitment to sustainability and climate action. This includes a focus on reducing Scope 1, 2, and 3 emissions, although specific figures for Radiometer Medical ApS are not available. In summary, while Radiometer Medical ApS does not provide its own emissions data, it aligns with the climate commitments and reduction strategies of Danaher Corporation, demonstrating a commitment to addressing climate change within its operational framework.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 138,341,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 219,166,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
How Carbon Intensive is Radiometer Medical ApS's Industry?
How Carbon Intensive is Radiometer Medical ApS's Location?
Radiometer Medical ApS's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Radiometer Medical ApS has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
